ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Last trade$13.48
Day change+$0.01 (+0.07%)
Day range$13.13 – $13.77
Volume1,426,113
Market cap$2.99B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.99B
Price / earnings
16.38×
Price / book
6.81×
Price / sales
5.76×
EV / sales
5.89×
EV / EBITDA
12.71×
Profitability
Earnings per share
$0.82
Return on assets
24.9%
Return on equity
41.6%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.45×
Current ratio
6.04×
Quick ratio
3.25×
Cash ratio
1.31×
Cash flow
Price / cash flow
21.23×
Price / free cash flow
22.48×
Free cash flow
$132.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ADMA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$141.1M
$124.4M
$114.49M
$139.16M
$134.22M
$121.98M
$114.8M
$117.55M
Cost of revenue
$41.25M
$38.12M
$33.74M
$50.35M
$58.64M
$54.76M
$53.71M
$54.22M
Gross profit
$99.86M
$86.28M
$80.75M
$88.82M
$75.59M
$67.23M
$61.1M
$63.33M
Selling, general and administrative
$26.56M
$26.74M
$26.74M
$23.51M
$21.78M
$22.21M
$24.08M
$23.32M
Research and development
$4.49M
$6.01M
$2.6M
$1.38M
$1.53M
$1.03M
$826K
$391K
Total operating expenses
$32.1M
$33.83M
$30.46M
$26.07M
$24.58M
$24.43M
$26.22M
$25.01M
Operating income
$67.76M
$52.45M
$50.29M
$62.75M
$51.01M
$42.8M
$34.88M
$38.32M
Interest expense
-$3.43M
-$3.42M
-$2.1M
-$1.63M
-$1.68M
-$1.83M
-$1.98M
-$2.88M
Income before taxes
$65.6M
$50.24M
$57.13M
$61.6M
$47.52M
$40.1M
$33.45M
$34.71M
Income taxes
$15.72M
$12.42M
$11.8M
$12.22M
$11.09M
$5.88M
$6.55M
-$77.18M
Net income
$49.88M
$37.82M
$45.33M
$49.38M
$36.43M
$34.22M
$26.9M
$111.9M
Net income attributable to common shareholders
$49.88M
$37.82M
$45.33M
$49.38M
$36.43M
$34.22M
$26.9M
$111.9M
EBITDA
$69.55M
$54.23M
$52.13M
$64.8M
$53.04M
$44.86M
$36.85M
$40.27M
Basic earnings per share
$0.22
$0.17
$0.19
$0.21
$0.15
$0.14
$0.11
$0.47
Diluted earnings per share
$0.22
$0.16
$0.19
$0.20
$0.15
$0.14
$0.11
$0.45
Recent news
Company coverage with links to the original publishers.
Zacks Premium offers investment research tools including the Zacks Rank and Style Scores to help investors identify stocks with the highest probability of outperformance. The Style Scores rate stocks on value, growth, and momentum characteristics, with the VGM Score combining all three. ADMA Biologics is highlighted as a stock to watch with a #3 Hold rank and strong momentum metrics.
ADMA Biologics shares gained 20.9% following better-than-expected Q3 2026 results. The company's lead product Asceniv drove revenue growth with a 31% year-over-year surge, while Bivigam sales declined 47.1% in the first nine months of 2026 due to competitive pressures. ADMA raised its minimum 2026 adjusted net income and EBITDA outlooks. Analysts recommend existing investors hold while new investors await a better entry point due to premium valuation.
Adma Biologics reported Q3 2026 earnings of $0.22 per share, beating consensus estimates of $0.19, with revenues of $141.1 million slightly exceeding expectations. However, the stock has declined 39.1% year-to-date versus the S&P 500's 10.6% gain. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Adma Biologics (ADMA) fell 2.89% on October 30, 2026, underperforming the S&P 500's 1.82% decline. Despite a strong monthly gain of 18.33%, the stock is rated a Hold with a Zacks Rank #3. The company is expected to report earnings on November 4, 2026, with anticipated EPS of $0.19 (up 18.75% YoY) and revenue of $139.8 million (up 4.16% YoY). ADMA trades at a Forward P/E of 15.13, below its industry average of 23.93.
ADMA Biologics announced it will report third quarter 2026 financial results on November 4, 2026, with a management conference call at 4:30 p.m. ET. The company, a biopharmaceutical manufacturer of specialty biologics including ASCENIV, BIVIGAM, and NABI-HB, operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.